Skip to main content
Log in

Hyperprolactinemia: neuroendocrine and diagnostic aspects

  • Review Article
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Lewis U.J., Singh R.P.N., Sinha Y.N., VanderLaan W.P. Electrophoretic evidence for human prolactin. J. Clin. Endocrinol. Metab. 33: 153, 1971.

    PubMed  CAS  Google Scholar 

  2. Hwuang P., Guyda H., Friesen H. A radioimmunoassay for human prolactin. Proc. Natl. Acad. Sci. USA 68: 1902, 1971.

    Google Scholar 

  3. Blackwell R.E. Diagnosis and management of prolactinomas. Fertil. Steril. 43: 5, 1985.

    PubMed  CAS  Google Scholar 

  4. Grossman A., Besser G.M. Prolactinomas. Br. Med. J. 290: 182, 1985.

    CAS  Google Scholar 

  5. Frantz A.G., Kleingerg D.L., Noel G.L. Studies on prolactin in man. Recent Prog. Horm. Res. 28: 527, 1972.

    PubMed  CAS  Google Scholar 

  6. Franks S., Jacobs H.S. Characterization and management of hyperprolactinemic amenorrhea. In: Crosignani P.G., Robyn C. (Eds.), Prolactin and human reproduction. Academic Press, New York, 1977, p. 245.

    Google Scholar 

  7. Boyar R.M., Kapen S., Finkelstein J.W., Parlow M., Sassin J.F., Fukushima D.K., Weitzmann E.D., Hellman L. Hypothalamic pituitary function in diverse hyperprolactinemic states. J. Clin. Invest. 53: 1588, 1974.

    PubMed Central  PubMed  CAS  Google Scholar 

  8. Malarkey W.B., Johnston J.C. Pituitary tumors and hyperprolactinemia. Arch. Intern. Med., 136: 4Q, 1976.

    Google Scholar 

  9. Malarkey W.B., Goodenow T.H., Lanese R.R. Diurnal variation of prolactin secretion differentiates pituitary tumors from primary empty sella syndrome. Am. J. Med. 69: 886, 1980.

    PubMed  CAS  Google Scholar 

  10. Andersen A.N., Tabor A. PRL, TSH, GH and LH responses to metoclopramide and breast feeding in normal and hyperprolactinemic women. Acta Endocrinol. (Copenh.) 100: 177, 1982.

    CAS  Google Scholar 

  11. Van Loon G.R. A defect in catecholamine neurons in patients with prolactin-secreting pituitary adenoma. Lancet 2: 868, 1978.

    PubMed  Google Scholar 

  12. Tucker H.G., Lankford H.V., Gardner D.F., Blackard W.G. Persistent defect in regulation of prolactin secretion after successful pituitary removal in women with amenorrhea-galactorrhea syndrome. J. Clin. Endocrinol. Metab. 51: 968, 1980.

    PubMed  CAS  Google Scholar 

  13. Melis G.B., Paoletti A.A., Mais V., Mastropasqua N.M., Strigini F., Fruzzetti F., Guarneri G., Gambacciani M., Fioretti P. The effect of the gabaergic drug, sodium valproate, on prolactin secretion in normal and hyperprolactinemic subjects. J. Clin. Endocrinol. Metab., 54: 485, 1982.

    PubMed  CAS  Google Scholar 

  14. Gonzales-Villipandio C., Szabo M., Frohman L.A. Central nervous system-mediated stimulation of prolactin secretion by Cimetidine, a histamine H2-receptor antagonist: impaired responsiveness in patients with prolactin-secreting tumors and idiopathic hyperprolactinemia. J. Clin. Endocrinol. Metab. 51: 1417, 1980.

    Google Scholar 

  15. Quigley M.E., Ishizuka B., Robert J.F., Yen S.S.C. The food-entrained prolactin and Cortisol release in late pregnancy and prolactinoma patients. J. Clin. Endocrinol. Metab. 54: 1109, 1982.

    PubMed  CAS  Google Scholar 

  16. Kletzky O.A., Davajan V., Mishell D.R., Nikoloff J.T., Mims R., March C.M., Nakamura R. A sequential pituitary stimulation test in normal subjects and in patients with amenorrhea-galactorrhea with pituitary tumors. J. Clin. Endocrinol. Metab. 45: 631, 1977.

    PubMed  CAS  Google Scholar 

  17. Hagen T.C., Sill A.J., Garthwaite T.L., Halverson G., Barkhowe H.I. Prolactin and growth hormone response in the amenorrhea-galactorrhea syndrome. Obstet. Gynecol. 56: 204, 1980.

    PubMed  CAS  Google Scholar 

  18. Seki K., Kato K., Shima K. Absence of growth hormone response to L-dopa and bromocriptine in hyperprolactinemic women with pituitary microadenoma. J. Clin. Endocrinol. Metab. 62: 783, 1986.

    PubMed  CAS  Google Scholar 

  19. Massara F., Camanni F., Belforte L., Vergnano V., Molinatti G.M. Increased Thyrotropin secretion induced by sulpiride in man. Clin. Endocrinol. (Oxf.) 9: 419, 1978.

    CAS  Google Scholar 

  20. Massara F., Camanni F., Martra M., Dolfin G.C., Muller E.E., Molinatti G.M. Reciprocal pattern of the thyrotropin and prolactin response to dopamine receptor blockade in women with physiological or pathological hyperprolactinemia. Clin. Endocrinol. (Oxf.) 18: 103, 1983.

    CAS  Google Scholar 

  21. Scanion M.F., Rodriguez-Arnao M.D., Mc Gregor A.M., Weightman D.R., Lewis M., Cook D.B, Gomez-Pan A., Hall R. Altered dopaminergic regulation of thyrotropin release in patients with prolactinomas: comparison with other tests of hypothalamic-pituitary function. Clin. Endocrinol. (Oxf.) 14: 133, 1981.

    Google Scholar 

  22. Quigley M.E., Judd S.J., Gilliland G.B., Yen S.S.C. Effects of dopamine antagonist on the release of gonadotropin and prolactin in normal women and women with hyperprolactinemic anovulation. J. Clin. Endocrinol. Metab. 48: 718, 1979.

    PubMed  CAS  Google Scholar 

  23. Quigley M.E., Yen S.S.C. Evidence for increased dopaminergic inhibition of secretion of thyrotropin-releasing hormone in hyperprolactinemic patients with pituitary microadenoma. Am. Obstet. Gynecol. 137: 653, 1980.

    CAS  Google Scholar 

  24. Tolis G. Prolactin: physiology and pathology. In: Krieger D.T., Hughes J.C. (Eds.), Neuroendocrinology. Sinauer Associates Inc Sunderland Massachusetts p. 321.1980.

  25. Bohnet H.G., Dahlen H.G. Wuttke W., Schneider H.P.G. Hyperprolactinemic anovulatory syndrome. J. Clin Endocrinol. Metab. 42: 132, 1976.

    PubMed  CAS  Google Scholar 

  26. Moult P.J.A., Rees L.H., Besser G.M. Pulsatile gonadotrophin secretion in hyperprolactinemic amenorrhea and the response to bromocriptine therapy. Clin. Endocrinol. (Oxf.) 16: 153, 1982.

    CAS  Google Scholar 

  27. Buckman M.T., Peake G.T., Srivastava L. Patterns of spontaneous LH release in normal and hyperprolactinemic women. Acta Endocrinol. (Copenh.) 97: 305, 1981.

    CAS  Google Scholar 

  28. Grossman A., Moult P.J., Mc Intyre H., Evans J., Silverstone T., Rees L.H., Besser G.M. Opiate mediation of amenorrhea in hyperprolactinemia and weight-loss related amenorrhea. Clin. Endocrinol. (Oxf.) 17: 379, 1982.

    CAS  Google Scholar 

  29. Muller E.E., Camanni F., Genazzani A.R., Casanueva F., Cocchi D., Locatelli V., Massara F., Mantegazza P. Dopamino-mimetic and antagonist drugs: diagnostic and therapeutic applications in endocrine disorders. Life Sci. 29: 867, 1981.

    PubMed  CAS  Google Scholar 

  30. Gennazzani A.R., Camanni F., Massara F., Picciolini F., Cocchi D., Belforte L., Muller E.E. A new pharmacological approach to the diagnosis of hyperprolactinemic states: the nomifensine test. Acta Endocrinol. (Copenh.) 92: 129, 1980.

    Google Scholar 

  31. Camanni F., Genazzani A.R., Massara F., De Leo V., Molinatti G.M., Muller E.E. Prolactin responsiveness to nomifensine in patients with hyperprolactinemia of tumorous or uncertain etiology. J. Clin. Endocrinol. Metab. 51: 650, 1980.

    PubMed  CAS  Google Scholar 

  32. Kamoi K., Tchuchida I, Sato H., Tanaka R., Ishiguro T., Kaneko K., Iwasaki I., Shibata A. Comparison of the responses in the nomifensine test in patients with hyperprolactinemia due to prolactin-secreting pituitary tumors and non-prloactin-secreting hypothalamic tumors. J. Clin. Endocrinol. Metab. 53: 1285, 1981

    PubMed  CAS  Google Scholar 

  33. Dallabonzana D., Spelta B., Botallo L., Oppizzi G., Silvestrini F., Chiodini P.G., Liuzzi A. Effects of nomifensine on growth hormone and prolactin secretion in normal subjects and in pathological hyperprolactinemia. J. Clin. Endocrinol. Metab. 54: 1125, 1982

    PubMed  CAS  Google Scholar 

  34. Camanni F., Gennazzani A.R., De Leo V., Molinatti G.M., Campagnoli C., Cocchi D., Muller E.E. Effect of two indirectly acting dopamine agonists on prolactin secretion in normo- and hyperprolactinemic subjects: comparison with the effect of nomifensine. Neuroendocrinology 33: 300, 1981

    PubMed  CAS  Google Scholar 

  35. De Leo V., Cella S.G., Camanni F., Gennazzani A.R., Muller E.E. Prolactin-lowering effect of amphetamine in normoprolactihemic subjects and in physiological and pathological hyperprolactinemia. Horm. Metab. Res. 15: 539, 1983.

    Google Scholar 

  36. Fine S.A., Frohman L.A. Loss of central nervous system component of dopaminergic inhibition of prolactin secretion in patients with prolactin-secreting pituitary tumors. J. Clin. Invest. 61: 973, 1978.

    PubMed Central  PubMed  CAS  Google Scholar 

  37. lanotta F., Fachinetti P., Fachinetti A., Pinotti G., Usellini L. Nomifensine, TRH and insulin-induced hypoglycaemia tests in the diagnosis of prolactinomas. J. Endocrinol. Invest. 6: 353, 1983.

    Google Scholar 

  38. Muller E.E., Cavagnini F., Martinez-Campos A., Mareschini C., Giovannini P., Novelli A., De Leo V. Dynamic testing of prolactin and growth hormone secretion in patients with neuroendocrine disorders. Acta Endocrinol. (Copenh.) 107: 155, 1984.

    CAS  Google Scholar 

  39. Casanueva F., Cocchi D., Locatelli V., Flauto C., Zambotti F., Bestetti G., Rossi G.L., Muller E.E. Defective central nervous system dopaminergic function in rats with estrogen-induced pituitary tumors, as assessed by plasma prolactin concentrations. Endocrinology: 110: 590, 1982.

    PubMed  CAS  Google Scholar 

  40. Sarkar D.K., Gottschall P.E., Meites J. Decline of tuberoinfundibular dopaminergic function resulting from chronic hyperprolactinemia in rats. Endocrinology 115: 1269, 1984.

    PubMed  CAS  Google Scholar 

  41. Bansal S., Lee L.A., Woolf P.D. Abnormal prolactin responsivity to dopaminergic suppression in hyperprolactinemic patients. Am. J. Med. 71: 961, 1981.

    PubMed  CAS  Google Scholar 

  42. Serri O., Kuchel O., Bun N.T., Somma M. Differential effects of low dose dopamine infusion on prolactin secretion in normal and hyperprolactinemic subjects. J. Clin. Endocrinol. Metab. 56: 255, 1983.

    PubMed  CAS  Google Scholar 

  43. Webb C.B., Thominet J.L., Barowsky H., Berelowitz M., Frohman L.A. Evidence for lactotroph dopamine resistence in idiopathic hyperprolactinemia. J. Clin. Endocrinol. Metab. 56: 1089, 1983.

    PubMed  CAS  Google Scholar 

  44. Ramsdell J.S., Bethea C.L., Wilson C.B., Jaffe R.B., Weiner R.I. Dihydroergocryptine binding to human prolactin secreting adenomas. 63rd Ann. Meet. Endocr. Soc, 981, p. 202.

  45. Cronin M.J., Cheung M.Y., Wilson C.B., Jaffe R.B., Weiner R.I. Tritiated spiperone binding to human anterior pituitaries and pituitary adenomas secreting prolactin growth homone and adrenocorticotropih. J. Clin. Endocrinol. Metab. 50: 387, 1980.

    PubMed  CAS  Google Scholar 

  46. Bression D., Brendi A.M., Martres M.P., Nousbaum A., Cesselin F., Racadot J., Peilion F. Dopaminergic receptors in human prolactin-secreting pituitary adenomas: a quantitative study. J. Clin. Endocrinol. Metab. 51: 1037, 1980.

    PubMed  CAS  Google Scholar 

  47. Martin M.C., Weiner R.I., Monroe S.E., Robert J.M., Licko V., Jaffa R.B. Prolactin secreting adenomas in women. VII Dopamine regulation of prolactin secretion. J. Clin. Endocrinol. Metab. 59: 485, 1984.

    PubMed  CAS  Google Scholar 

  48. Ho K.Y., Smythe G.A., Duncan M., Lazarus L. Dopamine infusion studies in patients with pathological hyperprolactinemia: evidence for normal prolactin suppressibility but abnormal dopamine metabolism. J. Clin. Endocrinol. Metab. 58: 128, 1984.

    PubMed  CAS  Google Scholar 

  49. Bethea C.L., Ramsdell J.S., Jaffe R.B., Wilson C.B., Weiner R.S. Characterization of dopaminergic regulation of human prolactin-secreting cells cultured on extracellar matrix. Endocrinology 108: 357, 1981.

    PubMed  CAS  Google Scholar 

  50. Thorner M.O., Fluckiger E., Caine D.B. Bromocriptine therapy for hyperprolactinemia and suppression of puerperal lactation. In: Thorner M.O., Fluckiger E., Caine D.B. (Eds.), Bromocriptine: a clinical and pharmacological review. Raven Press, New York, 1980, p. 56.

    Google Scholar 

  51. Cowden E.H., Thompson J.A., Doyle D., Ratcliffe J.G., Mac Pherson P., Teasdale G.M. Tests of prolactin secretion in the diagnosis of prolactinomas. Lancet 1: 1155, 1979.

    PubMed  CAS  Google Scholar 

  52. Massara F., Camanni F., Belforte L., Campagnoli C., Novi R.F., Molinatti G.M. Effects of sulpiride on plasma prolactin levels in women with puerperal or pathological hyperprolactinemia. Acta Endocrinol. (Copenh.) 95: 145, 1980.

    CAS  Google Scholar 

  53. Camanni F., Genazzani A.R., Massara F., La Rosa R., Cocchi D., Muller E.E. Prolactin releasing effect of domperidone in normoprolactinemic and hyperprolactinemic subjects. Neuroendocrinology, 30: 2, 1980.

    PubMed  CAS  Google Scholar 

  54. Ho K.Y., Smythe G.A., Lazarus L. Prolactin response to dopamine synthesis inhibition using monoiodothyrosine in subjects on oral contraceptives and patients with pathological hyperprolactinemia. J. Clin. Endocrinol. Metab., 56: 692, 1983.

    PubMed  CAS  Google Scholar 

  55. Ghigo E., Ciccarelli E., Novelli A., Massobrio M. Muller E.E., Camanni F. Prolactin and thyrotropin response to blockade of dopamine synthesis by monoidotyrosine in subjects with post-partum and pathological hyperprolactinemia. J. Endocrinol. Invest. 7: 525, 1985.

    Google Scholar 

  56. Ghigo E., Goffi S., Massara F. Prolactin and TSH response to alpha-methyl-l-tyrosine in normal subjects and in women with pathological hyperprolactinemia. Panminerva Medica 27: 21, 1985.

    PubMed  CAS  Google Scholar 

  57. Gudelsky G.A., Porter J.C. Release of newly synthesized dopamine into hypophyseal portal vasculature of the rat. Neuroendocrinology 104: 583, 1979.

    CAS  Google Scholar 

  58. Reymond M.J., Porter J.C. Hypotalamic secretion of dopamine after inhibition of aromatic L-amino acid decarboxilase activity. Endocrinology111: 1051, 1982.

    PubMed  CAS  Google Scholar 

  59. Demura R. Suda T., Wakabayashi T., Yoshimura M., Jibiki K., Odagiri E., Demura I., Shizume K. Plasma pituitary hormone response to the synthetic enkefaline analogue (FK 33–824) in normal subjects and patients with pituitary diseases. J. Clin. Endocrinol. Metab. 52: 263, 1981.

    PubMed  CAS  Google Scholar 

  60. Reymond M.J., Kaur C., Porter J.C. An inhibitory role for morphine on the release of dopamine into hypophysial portal blood and on the synthesis of dopamine in tuberoinfundibular neurons. Brain Res, 262: 253, 1983.

    PubMed  CAS  Google Scholar 

  61. Ghigo E., Goffi S., Molinatti G.M., Camanni F., Massara F. Prolactin and TSH response to both domperidone and TRH in normal and hyperprolactinemic women after dopamine synthesis blockade. Clin. Endocrinol. (Oxf.) 23: 155, 1985.

    CAS  Google Scholar 

  62. Crosignani P.G., Reschini E., Peracchi M., Lombroso G.C., Mattei A., Caccamo A. Failure of dopamine infusion to suppress the plasma prolactin response to sulpiride in normal and hyperprolactinemic subjects. J. Clin. Endocrinol. Metab. 45: 841, 1977.

    PubMed  CAS  Google Scholar 

  63. Quigley M.E., Judd S.J., Gilliland G.B., Yen S.S.C. Functional studies of dopamine control of prolactin secretion in normal women and women with hyperprolactinemic pituitary microadenoma. J. Clin. Endocrinol. Metab. 50: 994, 1980.

    PubMed  CAS  Google Scholar 

  64. Ferrari C., Rampini P., Benco R., Caldara R., Scarduelli C., Crosignani P.G. Functional characterization of hypothalamic hyperprolactinemia. J. Clin. Endocrinol. Metab. 55: 987, 1982.

    Google Scholar 

  65. Genazzani A.R., Lancranjan I., Picciolini E., La Rosa E., Audibert A. Evidence for central alpha-adrenergic inhibitory control of plasma prolactin. In: Abstract book Int. Symposium “Growth hormome and other biologically active peptides”. Ricerca Scientifica ed Educazione Permanente Suppl. 11, p.81 (Abstr.).

  66. Reichlin S., Molitch M. Neuroendocrine aspects of pituitary adenoma. In: Camanni F., Muller E.E. (Eds.), Pituitary hyperfunction. Raven Press, New York, 1984, p. 47.

    Google Scholar 

  67. Kaji H., Chihara K. Kita T., Kashio Y., Okimura Y., Fujita T. Lack of plasma prolactin response to intravenously injected vasoactive intestinal polypeptide in patients with prolactin-secreting adenoma. Acta Endocrinol. (Copenh.) 110: 445, 1985.

    CAS  Google Scholar 

  68. Le Dafniet M., Brandi M., Bression D., Racadot T., Peilion F. Evidence of receptors for thyrotropin-releasing hormone in human prolactin-secreting adenomas. J. Clin. Endocrinol. Metab. 57: 425, 1983.

    PubMed  Google Scholar 

  69. Nicosia S., Spada A., Borghi C., Cortellazzi L., Giannattasio G. Effects of vasoactive intestinal polypeptide adenomas. Stimulations of PRL release and activation of adenilate cyclase. FEBS Lett. 112: 159, 1980.

    PubMed  CAS  Google Scholar 

  70. Swearinger K.C., Nicoll C. Prolactin turnover in rat adenohypophysis in vivo: its evaluation as a method for estimating secretion rates. J. Endocrinol. 53: 1, 1972.

    Google Scholar 

  71. Knew-Hsiung L., Amenomori Y., Chiao-Ling C., Mettes J. Effects of central acting drugs on serum and pituitary prolactin levels in rats. Endocrinology 87: 667, 1987.

    Google Scholar 

  72. Jenkins J.S., Gilbert C.J., Ang V. Hypothalamic-pituitary function in patients with craniopharyngiomas. J. Clin. Endocrinol. Metab. 43: 394, 1976.

    PubMed  CAS  Google Scholar 

  73. Kapcala M.T., Molitch M.E., Post K.T., Miller B.J., Jackson J.M.D., Reichlin S. Galctorrhea, oligo-amenorrhea and hypeprolactinemia in patients with craniopharyngioma. J. Clin. Endocrinol. Metab. 53: 798, 1980.

    Google Scholar 

  74. Shas R.P., Leavens M.E., Samaan N.A. Galctorrhea, amenorrhea and hyperprolactinemia as manifestations of parasellar meningioma. Arch. Intern. Med. 140: 1608, 1980.

    Google Scholar 

  75. Kljin J.G.M., Lamberts S.W.J., De Jong F.H., Birkenhager J.C. The value of thyrotropin-releasing hormone test in patients with prolactin-secreting pituitary tumors and suprasellar non pituitary tumors. Fertil. Steril, 35: 155, 1981.

    Google Scholar 

  76. Healy D.L., Burger H.G. Sustained elevation of serum prolactin by metoclopramide: a clinical model of idiopathic hyperprolactinemia. J. Clin. Endocrinol. Metab. 46: 709, 1978.

    PubMed  CAS  Google Scholar 

  77. Nicoletti I., Filipponi P., Fedeli L., Sgrappini M., Gregorini G., Ambrosi F., Santeusanio F. Catecholamines and pituitary function. III. Restoration of the prolactin response to thyrotropin-releasing hormone by low dose dopamine infusion in women with pathological hyperprolactinemia. Horm. Res. 20: 202, 1984.

    PubMed  CAS  Google Scholar 

  78. Tater D., Charpentier G., Besson G., Rosselin G., Bercovici J.P. Le VIP lève l’inhibition de la secretion de prolactine induite par la dopamine chezles sujets presentant un prolactinome. C.R. Acad. Sci. 297: 331, 1983.

    CAS  Google Scholar 

  79. Camanni F., Massara F. L’iperprolattinemia. Fisopatologia, clinica e terapia. Masson Italia Editori, Milano, 1987.

    Google Scholar 

  80. Ghigo E., Ciccarelli E., Bianchi S.D., Gatti G., Molinatti G.M., Massara F., Muller E.E., Camanni F. Comparison of computed tomographic findings with tests of hypothalamo-pituitary function in 72 patients with hyperprolactinemia. Acta Endocrinol. (Copenh.) 112: 20, 1986.

    CAS  Google Scholar 

  81. Ciccarelli E., Ghigo E., Mazza E., Gandini G., Avataneo T., Rizzi G., Bertagna A., Camanni F. Pituitary computed tomography and dynamic tests of prolactin and thyrotropin secretion in 103 hyperprolactinemic patients. Panminerva Medica 29: 195, 1987.

    PubMed  CAS  Google Scholar 

  82. Scanion M.F., Weightman D.R., Maza B., Heath M., Shale D.J., Snow M.H., Hall R. Evidence for dopaminergic control of thyrotropin release in man. Lancet 2: 421, 1977.

    Google Scholar 

  83. Seki K., Uesato T., Kato K. Effects of dopamine antagonist (metoclopramide) on the release of the adenohypophyseal hormones in amenorrhoeic patients with and without hyperprolactinemia. Acta Endocrinol. (Copenh.) 101: 166, 1982.

    CAS  Google Scholar 

  84. Ho K.Y., Smythe G.A., Lazarus L. Enhanced hypothalamic inhibition of LH, TSH and GH release in patients with pathological hyperprolactinemia. Acta Endocrinol. (Copenh.) 108: 289, 1985.

    CAS  Google Scholar 

  85. Spitz I.M, Hoas M., Trestian S., Zylber-Haran E., Shilo S. The interrelationship between prolactin and thyrotropin secretion following dopaminergic blockage in patients with mild hyperprolactinemia and without any demonstrable pituitary tumor. Clin. Endocrinol. (Oxf.) 19: 285, 1983.

    CAS  Google Scholar 

  86. Moore K.E., Demarest K.T., Johnston C.A. Influence of prolactin on dopaminergic neuronal systems in the hypothalamus. Fed. Proc. 39: 2912, 1980.

    PubMed  CAS  Google Scholar 

  87. Faglia G., Spada A., Moriondo P., Giannattasio G., Nissim E., Elli R. What is the role of dopamine in the pathogenesis of prolactinomas? In: Camanni F., Muller E.E. (Eds.), Pituitary hyperfunction. Physiopathology and clinical aspects. Raven Press, New York, 1984, p. 279.

    Google Scholar 

  88. Camanni F., Ghigo E., Ciccarelli E., Massara F., Campagnoli C., Molinatti G.M., Muller E.E. Defective regulation of prolactin secretion after successful removal of prolactinomas. J. Clin. Endocrinol. Metab., 57: 1270, 1983.

    PubMed  CAS  Google Scholar 

  89. Camanni F., Ghigo E., Ciccarelli E., Savino L. Miola C., Bertagna A. Long-term follow-up of prolactinoma patients successfully cured by adenomectomy. In: A.R. Genazzani, U. Montemagno, C. Nappi, F. Petraglia (Eds.), The brain and female reproductive function. Parthenon Publ. Press, Casterton Hall, Carnforth, p. 561, 1987.

    Google Scholar 

  90. Erfurth E.M., Hedner P., Nilsson A. Basal and THR stimulated serum levels of TSH in patients with hyperprolactinaemia and in subjects on oestrogens treatment. Acta Endocrinol. (Copenh.) 102: 173, 1983.

    CAS  Google Scholar 

  91. Rodriguez-Arnao M.D, Peters J.R., Foord S.M., Dieguez C., Edwards C., Gomez-Pan A., Hall R. Newcombe R.G., Scanion M.F. Exaggerated circadian variation in basal thyrotropin (TSH) and in dopaminergic inhibition of TSH release in pathological hyperprolactinemia: evidence against a hypothalamic dopaminergic defect. J. Clin. Endocrinol. Metab., 57: 975, 1983.

    PubMed  CAS  Google Scholar 

  92. Nicoletti I., Filipponi P., Fedeli L., Ambrosi F., Gianmartino P., Spinozzi F., Santeusanio F. Cathecolamines and pituitary function. IV. Effects of low-dose dopamine infusion and long-term bromocriptine treatment on the abnormal thyrotroph (TSH) dynamics in patients with pathological hyperprolactinemia. Acta Endocrinol. (Copenh.) 11: 154, 1986.

    Google Scholar 

  93. Schlechte J.A., Sherman B.M., Chapler F.K., von-Gilder J. Long-term follow-up of women with surgically treated prolactin-secreting pituitary tumors. J. Clin. Endocrinol. Metab., 62: 1296, 1986.

    PubMed  CAS  Google Scholar 

  94. Schlechte J.A., Sherman B. Abnormal regulation of prolactin secretion after successful surgery for prolactin secreting pituitary tumors. Clin. Endocrinol. (Oxf.) 15: 165, 1981.

    CAS  Google Scholar 

  95. Frohman L.A., Berlowitz M., Gonzales C., Borowski H., Rao R., Lim V.S., Frohman M.A., Thominet J.L. Studies of dopaminergic mechanisms in hyperprolactinemic states. In: Crosignani P.G., Rubin B.L. (Eds.), Endocrinology of human infertility: new aspects. Academic Press, London, 1981, p. 39.

    Google Scholar 

  96. Jaquet P. Grisoli F., Guibut M., Lissitzky J.C., Carajon P. Prolactin secreting tumors: endocrine status before and after surgery in 33 women. J. Clin. Endocrinol. Metab. 46: 459, 1978.

    PubMed  CAS  Google Scholar 

  97. Murray F., Ostermans J., Sulewsy J., Page R., Bergland R., Hammonds J. Pituitary function following surgery for prolactinomas. Obstet. Gynecol. 54: 65, 1979.

    PubMed  CAS  Google Scholar 

  98. Barbarino A., De Marinis L., Menini E., Anile C., Maira G. Prolactin-secreting pituitary adenomas: prolactin dynamics before and after transsphenoidal surgery. Acta Endocrinol. (Copenh.) 91: 397, 1979.

    CAS  Google Scholar 

  99. Molitch M.E., Goodman R.H., Post K.D., Biller B.J., Moses A.C., King L.W., Feldman Z.T., Reichlin S. Surgical cure of prolactinoma reverses abnormal prolactin response to carbidopa/L-dopa. J. Clin. Endocrinol. Metab., 55: 1118, 1982.

    PubMed  CAS  Google Scholar 

  100. Arafah B.M., Brodkey J.S., Pearson O.H. Gradual recovery of lactotroph responsiveness to dynamic stimulation following surgical removal of prolactinomas: long-term follow-up studies. Metabolism 35: 905, 1986.

    PubMed  CAS  Google Scholar 

  101. Fuxe K. Brain catecholamine neurons as regulators of prolactin secretion and as a target for prolactin action. In Poceedings of the third International Meeting on Human Prolactin. Athens, Raven Press, New York, 1982.

    Google Scholar 

  102. Reymond M.J., Speciale S.G., Porter J.C. Dopamine in plasma of lateral and medial hypophysial portal vessels: evidence for regional variation in the release of hypothalamic dopamine into hypophysial portal blood. Endocrinology 112: 1958, 1983.

    PubMed  CAS  Google Scholar 

  103. Weiner R.I., Elias K.A., Monnet F. The role of vascular changes in the etiology of prolactin secreting pituitary tumors. In: Mac Leod R.M., Thorner M.O., Scapagnini V. (Eds.), Prolactin: basic and clinical correlates. Liviana Press, Padova, Fidia Research. Series, 1985, vol. 1, p. 641.

    Google Scholar 

  104. Erroi A., Bassetti M., Spada A., Giannattasio G. Microvasculature of human micro- and macroadenomas. A morphological study. Neuroendocrinology 43: 159, 1986.

    PubMed  CAS  Google Scholar 

  105. Sherman B.M., Wallace R.B., Chapler F.K., Luciano A.A., Bean J.A. In: Camanni F., Muller E.E. (Eds.), Pituitary hyper-function. Physiopathology and clinical aspects. Raven Press, New York, 1984, p. 167.

    Google Scholar 

  106. Costello R.T. Subclinical adenomas of the pituitary gland. Am. J. Pathol. 12: 205, 1983.

    Google Scholar 

  107. Burrow G.N., Wortzmann G., Rewcastle N.B., Holtgate R.C., Kovacs K. Microadenomas of the pituitary and abnormal sellar tomograms in an unselected autopsy series. N. Engl. J. Med. 304: 156, 1981.

    PubMed  CAS  Google Scholar 

  108. Harris P.E., Valcavi R., Artioli C., Casioli P., Foord S.M., Dieguez C., Peters J.R., Hall R., Scanion M.F. The influence of oestrogens on the sensitivity of prolactin, TSH and LH to the inhibitory action of dopamine in hyperprolactinemic patients. In: Mac Leod R.M., Thorner M.O., Scapagnini U. (Eds.), Prolactin. Basic and clinical correlates. Liviana Press, Padova, Fidia Research. Series, 1985, vol. 1, p. 753.

    Google Scholar 

  109. Demarest K.T., Mc Kay, Riegle G.D., Moore K.I. Biochemical indexes of tuberoinfudibular dopaminergic neuronal activities during lactation: a lack of response to prolactin. Neuroendocrinology 36: 130, 1983.

    PubMed  CAS  Google Scholar 

  110. Ghigo E., Pogliano G.F., Campagnoli C., Bertagna A., Camanni F., Massara F. Estrogenic treatment does not modify the PRL and TSH responses to domperidone and TRH in patients with tumoral hyperprolactinemia. J. Endocrinol. Invest. 7: 525, 1984.

    PubMed  CAS  Google Scholar 

  111. Schlechte H., Sherman B., Halmi N., van Gilder J., Chapler F., Dolan K., Granner D., Duello T., Harris C. Prolactin-secreting pituitary tumors in amenorrheic women. A comprehensive study. Endocr. Rev. 1: 295, 1980.

    PubMed  CAS  Google Scholar 

  112. Massara F., Genazzani A.R., Camanni F., DeLeo V., Molinatti G.M., Muller E.E. Tests of prolactin secretion in the diagnosis of hyperprolactinemic states: nomifensine and domperidone. Fertil. Steril. 35: 149, 1981.

    PubMed  CAS  Google Scholar 

  113. Pontiroli A.E., Falsetti L., Voltolini A.M., Albertetto M., Pellicciotta G., De Pasqua A., Girardi A.M., Pozza G. Benserazide, a stimulator of prolactin release: a new test in the diagnosis of pituitary prolactin secreting tumors. Acta Endocrinol. (Copenh.) 98: 326, 1981.

    CAS  Google Scholar 

  114. Pontiroli A.E., Loda G., Roggia A., Scagliolo P., Falsetti L. Benserazide and nomifensine in the diagnosis of prolactin-secreting pituitary adenomas. Acta Endocrinol. (Copenh.) 101: 171, 1982.

    CAS  Google Scholar 

  115. Iodice I, Lombardi G., Tommaselli A., Rossi R., Annunziata L., Minozzi M. Agreement of prolactin response to Cimetidine and nomifensine in patients with prolactin-secreting tumors and idiopathic hyperprolactinemia. Neuroendocrinology 35: 333, 1982.

    PubMed  CAS  Google Scholar 

  116. Ferrari C., Crosignani P.G., Caldara R., Picciotti M.C., Malinverni A., Barattini G., Rampini P., Telloli P. Failure of nomifensine administration to discriminate between tumorous and nontumorous hyperprolactinemias. J. Clin. Endocrinol. Metab. 50: 23, 1980.

    PubMed  CAS  Google Scholar 

  117. Moriondo P., Travaglini P., Nissim M., Faglia G. Evaluation of two inhibitory tests (nomifensine and L-dopa Carbidopa) for the diagnosis of hyperprolactinemic states. Clin. Endocrinol. (Oxf.) 13: 525, 1980.

    CAS  Google Scholar 

  118. Abboud C.F., Lows E.R. Diagnosis of pituitary tumours. Endocrinol. Metab. Clin. North Am. 17: 241, 1988.

    PubMed  CAS  Google Scholar 

  119. Balagura S., Frantz A.G., Housepian E.M. Carmel P.W. The specificity of serum prolactin as a diagnostic indicator of pituitary adenoma. J. Neurosurg. 51: 42, 1979.

    PubMed  CAS  Google Scholar 

  120. Sklar G.A., Grumbach M.M., Koplan S.L., Conte F.A. Hormonal and metabolic abnormalities associated with central nervous system germinoma in children and adolescent and the effect of the therapy: report of 10 patients. J. Clin. Endocrinol. Metab. 52: 9, 1981.

    PubMed  CAS  Google Scholar 

  121. Lundberg P.O., Osterman P.D., Wide L. Serum prolactin in patients with hypothalamus and pituitary disorders. J. Neurosurg. 55: 194, 1981.

    PubMed  CAS  Google Scholar 

  122. Ferrari C., Rampini P., Benco R., Caldara R., Scarduelli C., Crosignani P.G. Functional characterization of hypothalamic hyperprolactinemia. J. Clin. Endocrinol. Metab. 55: 897, 1982.

    PubMed  CAS  Google Scholar 

  123. Scanion M.F., Peters J.R., Salvador J., Richards S.H., John R., Howell S., Williams E.D., Thomas J.P., Hall R. The preoperative and postoperative investigation of TSH and prolactin release in the management of patients with hyperprolactinemia due to prolactinomas and nonfunctional pituitary tumours: relationship to adenoma size at surgery. Clin. Endocrinol. (Oxf.) 24: 435, 1986.

    Google Scholar 

  124. Ciccarelli E., Ghigo E., Savino L., Miola C., Camanni F. Letter to Editor. Clin. Endocrinol. (Oxf,) 25: 749, 1986.

    CAS  Google Scholar 

  125. Randall R.V., Scheithauer R.W., Laws E.R., Abboud C.F., Ebersold M.J., Kao P.C. Pituitary adenomas associated with hyperprolactinemia: a clinical and immunohistochemical study on 97 patients operated on transsphenoidally. Mayo Clin. Proc. 60: 753, 1985.

    PubMed  CAS  Google Scholar 

  126. Molitch M.E., Reichlin S. Hypothalamic hyperprolactinemia: neuroendocrine regulation of prolactin secretion in patients with lesions of the hypothalamus and pituitary stalk. In: Mac Leod R.M., Thorner M.O., Scapagnini U. (Eds.), Prolactin. Basic and clinical correlates. Liviana Press, Padova, Fidia Research. Series, 1985, vol. 1, p. 709.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Camanni, F., Ciccarelli, E., Ghigo, E. et al. Hyperprolactinemia: neuroendocrine and diagnostic aspects. J Endocrinol Invest 12, 653–668 (1989). https://doi.org/10.1007/BF03350030

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03350030

Key-words

Navigation